Marimed (MRMD) Income from Continuing Operations (2011 - 2026)
Marimed (MRMD) posted quarterly Income from Continuing Operations of 3767000.0 for Q1 2026, up 31.25% year-over-year from 2870170.07 in Q1 2025, and up 18.83% quarter-over-quarter from 4641000.0 in Q4 2025.
Marimed (MRMD) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Marimed (MRMD) has reported Income from Continuing Operations for 16 consecutive years, with 3767000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 31.25% year-over-year to 3767000.0; the TTM figure through Mar 2026 stood at 12619000.0 (up 22.92% YoY), while the FY2025 annual figure was 14456000.0, down 16.3% from the prior year.
- Income from Continuing Operations improved to 3767000.0 in Q1 2026 per MRMD's latest filing, from 4641000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4749000.0 in Q4 2022 and bottomed at 10139000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 1922470.59 across 5 years, with a median of 1292000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 174.13% — and 2025, when it plunged 324.07%.
- Marimed's Income from Continuing Operations stood at 4749000.0 in 2022, then plunged by 313.5% to 10139000.0 in 2023, then increased by 18.49% to 8264000.0 in 2024, then jumped by 43.84% to 4641000.0 in 2025, then climbed by 18.83% to 3767000.0 in 2026.
- Business Quant data shows MRMD's Income from Continuing Operations at 3767000.0 in Q1 2026, 4641000.0 in Q4 2025, and 2941000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Marimed | 27.77 Mn | 19.33 Mn | 16.23 Mn | -3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.57 Mn |
| Mar 31, 2026 | -3.77 Mn |
| Dec 31, 2025 | -4.64 Mn |
| Sep 30, 2025 | -2.94 Mn |
| Jun 30, 2025 | -1.27 Mn |
| Mar 31, 2025 | -5.48 Mn |
| Dec 31, 2024 | -8.26 Mn |
| Sep 30, 2024 | -990,000.00 |
| Jun 30, 2024 | -1.64 Mn |
| Mar 31, 2024 | -1.29 Mn |
| Dec 31, 2023 | -10.14 Mn |
| Sep 30, 2023 | -4.27 Mn |
| Jun 30, 2023 | -935,000.00 |
| Mar 31, 2023 | -664,000.00 |
| Dec 31, 2022 | 4.75 Mn |
| Sep 30, 2022 | 2.72 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | 4.24 Mn |
| Dec 31, 2021 | -6.41 Mn |
| Sep 30, 2021 | 2.12 Mn |